Denosumab Prolia® / Xgeva®
The SHIKARI® Denosumab portfolio combines quantitative free-drug measurement with qualitative and quantitative anti-denosumab antibody assays for method-controlled research.
Why Denosumab is relevant to biological-drug monitoring research
Denosumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Denosumab is a fully human IgG2 monoclonal antibody against RANK ligand (RANKL), reducing osteoclast formation, function and survival. Source ↗
Approved Indications
For the Prolia®-family regimen relevant to this page, EMA-authorised uses include osteoporosis and defined treatment-associated bone-loss settings in adults. EMA source ↗
60 mg SC Exposure
Regulatory pharmacokinetic data after a 60 mg subcutaneous dose provide exposure context rather than a treatment target:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Denosumab research assays
Ligand-binding ELISA for quantitative analysis of free denosumab in human serum or plasma.
Quantitative ELISA for anti-denosumab antibodies in human serum or plasma, with an assay-specific confirmation procedure.
Qualitative ELISA for reactive or non-reactive assessment of anti-denosumab antibodies using assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-DEN | DEN-FD-PRO | Quantitative | Free denosumab | Human serum / plasma | 10 µL | 70 min | LOD 10 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATD | DEN-QNS-PRO | Quantitative | Anti-denosumab antibodies | Human serum / plasma | 5 µL | 140 min | LOD 18.75 ng/mL; LOQ 31.25 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATD | DEN-QLS-PRO | Qualitative | Anti-denosumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Publications Using SHIKARI® Denosumab Kits 2
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Denosumab research study?
Matrix Biotek can help identify the appropriate Denosumab assay and prepare regional quotation and delivery information.